Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 4
1996 6
1997 1
1998 4
1999 9
2000 11
2001 20
2002 26
2003 16
2004 27
2005 30
2006 47
2007 54
2008 53
2009 64
2010 83
2011 93
2012 99
2013 103
2014 109
2015 128
2016 100
2017 72
2018 82
2019 73
2020 8
Text availability
Article attribute
Article type
Publication date

Search Results

1,160 results
Results by year
Filters applied: . Clear all
Page 1
Lapatinib.
Voigtlaender M, Schneider-Merck T, Trepel M. Voigtlaender M, et al. Recent Results Cancer Res. 2018;211:19-44. doi: 10.1007/978-3-319-91442-8_2. Recent Results Cancer Res. 2018. PMID: 30069757 Review.
HER2: An emerging target in colorectal cancer.
Greally M, Kelly CM, Cercek A. Greally M, et al. Curr Probl Cancer. 2018 Nov;42(6):560-571. doi: 10.1016/j.currproblcancer.2018.07.001. Epub 2018 Jul 19. Curr Probl Cancer. 2018. PMID: 30100092 Review.
Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib.
Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, Perou CM, Winer EP, Hudis CA. Carey LA, et al. J Clin Oncol. 2016 Feb 20;34(6):542-9. doi: 10.1200/JCO.2015.62.1268. Epub 2015 Nov 2. J Clin Oncol. 2016. PMID: 26527775 Free PMC article. Clinical Trial.
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
Jang J, Son J, Park E, Kosaka T, Saxon JA, De Clercq DJH, Choi HG, Tanizaki J, Eck MJ, Jänne PA, Gray NS. Jang J, et al. Angew Chem Int Ed Engl. 2018 Sep 3;57(36):11629-11633. doi: 10.1002/anie.201805187. Epub 2018 Aug 3. Angew Chem Int Ed Engl. 2018. PMID: 29978938 Free PMC article.
Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.
Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ. Johnston SRD, et al. J Clin Oncol. 2018 Mar 10;36(8):741-748. doi: 10.1200/JCO.2017.74.7824. Epub 2017 Dec 15. J Clin Oncol. 2018. PMID: 29244528 Clinical Trial.
Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma.
Curea FG, Hebbar M, Ilie SM, Bacinschi XE, Trifanescu OG, Botnariuc I, Anghel RM. Curea FG, et al. Cancer Biother Radiopharm. 2017 Dec;32(10):351-363. doi: 10.1089/cbr.2017.2249. Cancer Biother Radiopharm. 2017. PMID: 29265917 Review.
1,160 results
Jump to page
Feedback